View ValuationImpediMed 향후 성장Future 기준 점검 2/6ImpediMed은 연간 수입과 매출이 각각 40.8%와 29.4% 증가할 것으로 예상되고 EPS는 연간 65.3%만큼 증가할 것으로 예상됩니다.핵심 정보40.8%이익 성장률65.30%EPS 성장률Medical Equipment 이익 성장16.1%매출 성장률29.4%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트12 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 06+ 1 more updateImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million.ImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,020,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing공시 • Apr 08+ 1 more updateImpediMed Limited Announces Chief Executive Officer ChangesImpediMed Limited announced the appointment of Erik Anderson as Chief Executive Officer. Anderson, who joined the company's Board of Directors in February 2026, succeeds Dr. Parmjot Bains. His appointment is effective April 7, 2026. Anderson's appointment comes as ImpediMed's business gains momentum with its Breast Cancer Related Lymphedema (BCRL) business. The Board determined that the next phase of growth requires a step change in commercial execution, particularly in the United States. Anderson's appointment reflects a focus on accelerating revenue growth, expanding health system adoption, managing costs, and advancing the company toward cash flow break-even and long-term value creation. Anderson brings to ImpediMed extensive commercial leadership experience in the US medical technology sector. Most recently, he served as President of the Breast and Skeletal Health Division at Hologic Inc. . During his tenure at Hologic, he led a large, multi-franchise commercial organization and grew one of the company's largest business units—a $1.6+ billion global franchise. He also brings deep expertise in healthcare delivery, including hospital sales, clinical adoption, and reimbursement, along with strong relationships across health systems and key stakeholders aligned with ImpediMed's growth priorities in BCRL, body composition, and heart health. With this experience, Anderson is well-positioned to lead ImpediMed's next phase of growth, expanding sales and distribution across U.S. health systems. Bains will continue in an advisory role through June 30, 2026, to support a smooth leadership transition.공시 • Jan 27ImpediMed Limited to Report Q2, 2026 Results on Jan 29, 2026ImpediMed Limited announced that they will report Q2, 2026 results on Jan 29, 2026공시 • Oct 24ImpediMed Limited to Report Q1, 2026 Results on Oct 30, 2025ImpediMed Limited announced that they will report Q1, 2026 results on Oct 30, 2025공시 • Sep 19ImpediMed Limited, Annual General Meeting, Nov 18, 2025ImpediMed Limited, Annual General Meeting, Nov 18, 2025.공시 • Jul 16ImpediMed Limited to Report Q4, 2025 Results on Jul 31, 2025ImpediMed Limited announced that they will report Q4, 2025 results on Jul 31, 2025공시 • Apr 17ImpediMed Limited to Report Q3, 2025 Results on Apr 30, 2025ImpediMed Limited announced that they will report Q3, 2025 results on Apr 30, 2025공시 • Jan 28ImpediMed Limited to Report Q2, 2025 Results on Jan 31, 2025ImpediMed Limited announced that they will report Q2, 2025 results on Jan 31, 2025공시 • Oct 15ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024ImpediMed Limited announced that they will report Q1, 2025 results on Oct 22, 2024공시 • Sep 27ImpediMed Limited, Annual General Meeting, Nov 19, 2024ImpediMed Limited, Annual General Meeting, Nov 19, 2024.공시 • Aug 23ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024ImpediMed Limited announced that they will report fiscal year 2024 results Pre-Market on Aug 29, 2024공시 • Jul 22+ 3 more updatesImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basisAs announced in November 2023, Dr. Parmjot Bains, CEO and Managing Director commenced in their roles in an interim capacity. The Board of ImpediMed Limited confirmed the appointment of Dr. Bains as Chief Executive Officer on an ongoing basis. In the 6-month period in their interim roles, Dr. Bains has implemented a number of significant changes across the business to ensure the Company is in the best position to achieve growth and profitability and ensure all patients at risk of cancer related lymphedema can access ImpediMed's unique technology.공시 • Jun 08ImpediMed Limited Appoints Fiona Bones as A Non-Executive DirectorThe Board of ImpediMed Limited announced the appointment of Ms Fiona Bones as a non-Executive Director of the Company, effective 07 June 2024. Ms Bones is currently VP of Finance, International Controller at Google and has worked at Google for over 20 years. Ms Bones is a Fellow of the Association of Chartered Certified Accountants, UK and Ireland and brings global experience in finance, corporate governance, and systems transformation.공시 • Apr 20ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024ImpediMed Limited announced that they will report Q3, 2024 results on Apr 30, 2024공시 • Apr 11ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual MeetingImpediMed announced that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on April 12, 2024. The study, titled "Timing of Breast Cancer-related Lymphedema Development Over Three Years: Observations from a Large, Prospective Randomized Screening Trial," revealed that patients at risk of developing breast cancer related lymphedema (BRCL) should continue to be monitored for three years following the completion of cancer treatment, as patients could trigger at any time over this period. The results are part of PREVENT, the largest randomized control trial to assess lymphedema prevention, in 1200 women, which monitored progression to BCRL following intervention for BCRL assessed by both bioimpedance spectroscopy (BIS) and a tape measure, demonstrating lower progression to chronic lymphedema with early detection using BIS and intervention versus using tape measure. Lymphedema, a common consequence of cancer treatment, poses significant challenges in healthcare. According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk. ImpediMed has the only FDA-cleared BIS technology for the clinical assessment of lymphedema. The Company's SOZO® Digital Health Platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with US payors now providing coverage for over 140 million covered lives. The PREVENT trial is a pivotal study and the largest randomized controlled trial to assess lymphedema prevention. The study enrolled 1,200 patients across 10 trial sites in the US and Australia, involving 13 hospitals, including Vanderbilt University, Mayo Clinic and MD Anderson. The trial was conducted over six and a half years and patients were followed for up to three years, with the primary aim to determine if early intervention in patients with subclinical detection of extracellular fluid accumulation via bioimpedance spectroscopy results in a lower rate of lymphedema progression versus the rate when tape measure is used for subclinical detection. The manuscript is published in Lymphatic Research and Biology. The results of the trial demonstrated that patients with early detection with L-Dex™ technology and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure. The difference is statistically significant (p=0.016) as well as being clinically significant for patients and clinicians. This represents an absolute reduction of 11.3% and relative reduction of 59% in lymphedema progression at three years.공시 • Jan 23ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024ImpediMed Limited announced that they will report first half, 2024 results on Feb 27, 2024공시 • Nov 20+ 2 more updatesImpediMed Limited Announces CFO ChangesImpediMed Limited announced leadership and Board changes to drive growth and manage costs. When elected, the Board announced a review of ImpediMed's strategy to ensure it was maximising the potential opportunities to transition to a high growth and profitable business. To date, the Board has considered the Company's operational readiness, approach to execution and cost structure. The review identified a very capable core management team, a distinctive product portfolio and an undeniable opportunity. However, more is needed to deliver robust execution and control costs. Given these challenges and the strong endorsement for change from ImpediMed shareholders at the recent General Meeting, the Board has determined that action now is appropriate. Tim Cruickshank has stepped down as CFO and the Board is discussing transition arrangements with him. Chair McGregor Grant assumes the responsibilities of CFO effective immediately, in an interim capacity and will be an Executive Chairman. The Chair, McGregor Grant will work closely with Dr. Bains as CFO, with a clear focus on managing costs. managing costs. For the last 12 years Mr. Grant was CFO and company Secretary of Nanosonics Limited. As well as leading financial strategy, Mr. Grant played a key role in developing and implementing corporate strategy. He was also responsible for operational functions including IT, legal and facilities management. During Mr. Grant's tenure at Nanosonics revenue grew from $2 million to $166 million. Together, Dr. Bains and Mr. Grant have extensive strategic, sales & marketing, financial and operational experience in high growth MedTech/healthcare businesses and will ensure stability and continuity of the business' operations. The Board recognises the significant talent within the senior management team, and Dr. Bains and Mr. Grant look forward to working closely with them to ensure the entire ImpediMed team remains focused on execution. Dr. Bains and Mr. Grant will also work closely with the management team to more deeply examine the Company's strategic and operational plans and its cost base to maximise the commercial opportunity and deliver value to its shareholders. Dr. Bains and Mr. Grant have been appointed to their roles in an interim capacity, which is expected to be in place for a period of up to six months while they assess the requirements of the business.공시 • Oct 24ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023ImpediMed Limited announced that they will report Q1, 2024 results on Oct 31, 2023공시 • Oct 12ImpediMed Limited, Annual General Meeting, Nov 30, 2023ImpediMed Limited, Annual General Meeting, Nov 30, 2023, at 10:01 E. Australia Standard Time.공시 • Sep 27ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical OfficerImpediMed Limited announced the appointment of Steven Chen, MD, MBA as Chief Medical Officer effective 26 September 2023. Dr. Chen is a board-certified surgical oncologist who brings strong business acumen and extensive leadership experience in cancer care and the healthcare industry. Dr. Chen's previous leadership and experience: Chief Medical Officer of Avelas Biosciences, a clinical stage drug-device company dedicated to improving cancer care. Chief of Breast Surgery, University of California Davis Medical Center. Associate Program Director of the surgical oncology training program at City of Hope National Medical Center, Duarte, California. Past President, American Society of Breast Surgeons (ASBrS). Clinical training at the John Wayne Cancer Institute, the University of Michigan and the Center for Health Care Economics. Over 70 publications and 5,000 citations. The University of California Davis, the City of Hope, and the University of Michigan are members of the National Comprehensive Cancer Network (NCCN®). Most recently, Dr. Chen served as the Chief Medical Officer of Avelas, a clinical stage drug-device company dedicated to improving cancer care. There, he successfully oversaw their lead asset through Investigational New Drug (IND) application and first in human studies through pivotal trials and established the company's clinical strategy to support commercialisation and reimbursement. Previously, Dr. Chen served as the Chief of Breast Surgery at UC Davis Medical Center, followed by a position as an Associate Professor of Surgery and as the Associate Program Director of the surgical oncology training program at City of Hope National Medical Center in Duarte, California. He is a past President of the American Society of Breast Surgeons and serves or served on committees for a number of professional societies including the American Medical Association, the Society of Surgical Oncology, and the American College of Surgeons. Dr. Chen is a practicing surgeon in San Diego, California and the Director of Surgical Oncology at OasisMD. Dr. Chen received his medical degree and completed general surgery and critical care residencies at the University of Michigan, followed by a surgical oncology fellowship at the John Wayne Cancer Institute. Dr. Chen also obtained his master's in business administration at the University of Michigan's Ross School of Business.공시 • Jul 17ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023ImpediMed Limited announced that they will report Q4, 2023 results on Jul 24, 2023공시 • Jul 06ImpediMed Limited Appoints Daniel Sharp as DirectorImpediMed Limited appointed Mr. Daniel Sharp as director, date of appointment is July 1, 2023.공시 • Jan 24ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023ImpediMed Limited announced that they will report Q2, 2023 results on Jan 30, 2023이익 및 매출 성장 예측OTCPK:IPDQ.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202828-7-9-436/30/202720-14-16-1336/30/202615-22-22-18212/31/202514-24-16-15N/A9/30/202513-24-16-15N/A6/30/202513-23-16-15N/A3/31/202512-22-18-17N/A12/31/202412-21-21-19N/A9/30/202411-21-21-18N/A6/30/202410-20-21-18N/A3/31/202410-20-19-15N/A12/31/202310-19-18-13N/A9/30/202311-20-21-15N/A6/30/202311-21-24-18N/A3/31/202311-21-25-20N/A12/31/202211-22-27-22N/A9/30/202211-21-24-19N/A6/30/202211-20-21-16N/A3/31/202210-20-19-14N/A12/31/202110-19-17-13N/A9/30/20219-20-16-13N/A6/30/20218-21-16-13N/A3/31/20217-20-17-15N/A12/31/20206-19-18-16N/A9/30/20206-20-20-18N/A6/30/20206-21-21-19N/A12/31/20195-25-22-20N/A9/30/20195-24N/A-20N/A6/30/20194-24N/A-20N/A12/31/20184-25N/A-21N/A9/30/20183-26N/A-22N/A6/30/20183-27N/A-23N/A3/31/20184-28N/AN/AN/A12/31/20174-28N/A-26N/A9/30/20175-28N/A-26N/A6/30/20176-28N/A-26N/A3/31/20176-28N/A-25N/A12/31/20166-29N/A-25N/A9/30/20166-27N/A-24N/A6/30/20166-26N/A-22N/A3/31/20166-23N/A-19N/A12/31/20155-20N/A-16N/A9/30/20155-17N/A-13N/A6/30/20155-15N/A-11N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: IPDQ.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: IPDQ.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: IPDQ.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: IPDQ.F 의 수익(연간 29.4%)이 US 시장(연간 11.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: IPDQ.F 의 수익(연간 29.4%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: IPDQ.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 16:19종가2026/05/15 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ImpediMed Limited는 5명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관James WilliamsonBell PotterMartyn JacobsBell PotterShane StoreyCanaccord Genuity2명의 분석가 더 보기
공시 • May 06+ 1 more updateImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million.ImpediMed Limited has completed a Follow-on Equity Offering in the amount of AUD 13.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 300,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,020,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
공시 • Apr 08+ 1 more updateImpediMed Limited Announces Chief Executive Officer ChangesImpediMed Limited announced the appointment of Erik Anderson as Chief Executive Officer. Anderson, who joined the company's Board of Directors in February 2026, succeeds Dr. Parmjot Bains. His appointment is effective April 7, 2026. Anderson's appointment comes as ImpediMed's business gains momentum with its Breast Cancer Related Lymphedema (BCRL) business. The Board determined that the next phase of growth requires a step change in commercial execution, particularly in the United States. Anderson's appointment reflects a focus on accelerating revenue growth, expanding health system adoption, managing costs, and advancing the company toward cash flow break-even and long-term value creation. Anderson brings to ImpediMed extensive commercial leadership experience in the US medical technology sector. Most recently, he served as President of the Breast and Skeletal Health Division at Hologic Inc. . During his tenure at Hologic, he led a large, multi-franchise commercial organization and grew one of the company's largest business units—a $1.6+ billion global franchise. He also brings deep expertise in healthcare delivery, including hospital sales, clinical adoption, and reimbursement, along with strong relationships across health systems and key stakeholders aligned with ImpediMed's growth priorities in BCRL, body composition, and heart health. With this experience, Anderson is well-positioned to lead ImpediMed's next phase of growth, expanding sales and distribution across U.S. health systems. Bains will continue in an advisory role through June 30, 2026, to support a smooth leadership transition.
공시 • Jan 27ImpediMed Limited to Report Q2, 2026 Results on Jan 29, 2026ImpediMed Limited announced that they will report Q2, 2026 results on Jan 29, 2026
공시 • Oct 24ImpediMed Limited to Report Q1, 2026 Results on Oct 30, 2025ImpediMed Limited announced that they will report Q1, 2026 results on Oct 30, 2025
공시 • Sep 19ImpediMed Limited, Annual General Meeting, Nov 18, 2025ImpediMed Limited, Annual General Meeting, Nov 18, 2025.
공시 • Jul 16ImpediMed Limited to Report Q4, 2025 Results on Jul 31, 2025ImpediMed Limited announced that they will report Q4, 2025 results on Jul 31, 2025
공시 • Apr 17ImpediMed Limited to Report Q3, 2025 Results on Apr 30, 2025ImpediMed Limited announced that they will report Q3, 2025 results on Apr 30, 2025
공시 • Jan 28ImpediMed Limited to Report Q2, 2025 Results on Jan 31, 2025ImpediMed Limited announced that they will report Q2, 2025 results on Jan 31, 2025
공시 • Oct 15ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024ImpediMed Limited announced that they will report Q1, 2025 results on Oct 22, 2024
공시 • Sep 27ImpediMed Limited, Annual General Meeting, Nov 19, 2024ImpediMed Limited, Annual General Meeting, Nov 19, 2024.
공시 • Aug 23ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024ImpediMed Limited announced that they will report fiscal year 2024 results Pre-Market on Aug 29, 2024
공시 • Jul 22+ 3 more updatesImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basisAs announced in November 2023, Dr. Parmjot Bains, CEO and Managing Director commenced in their roles in an interim capacity. The Board of ImpediMed Limited confirmed the appointment of Dr. Bains as Chief Executive Officer on an ongoing basis. In the 6-month period in their interim roles, Dr. Bains has implemented a number of significant changes across the business to ensure the Company is in the best position to achieve growth and profitability and ensure all patients at risk of cancer related lymphedema can access ImpediMed's unique technology.
공시 • Jun 08ImpediMed Limited Appoints Fiona Bones as A Non-Executive DirectorThe Board of ImpediMed Limited announced the appointment of Ms Fiona Bones as a non-Executive Director of the Company, effective 07 June 2024. Ms Bones is currently VP of Finance, International Controller at Google and has worked at Google for over 20 years. Ms Bones is a Fellow of the Association of Chartered Certified Accountants, UK and Ireland and brings global experience in finance, corporate governance, and systems transformation.
공시 • Apr 20ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024ImpediMed Limited announced that they will report Q3, 2024 results on Apr 30, 2024
공시 • Apr 11ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual MeetingImpediMed announced that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on April 12, 2024. The study, titled "Timing of Breast Cancer-related Lymphedema Development Over Three Years: Observations from a Large, Prospective Randomized Screening Trial," revealed that patients at risk of developing breast cancer related lymphedema (BRCL) should continue to be monitored for three years following the completion of cancer treatment, as patients could trigger at any time over this period. The results are part of PREVENT, the largest randomized control trial to assess lymphedema prevention, in 1200 women, which monitored progression to BCRL following intervention for BCRL assessed by both bioimpedance spectroscopy (BIS) and a tape measure, demonstrating lower progression to chronic lymphedema with early detection using BIS and intervention versus using tape measure. Lymphedema, a common consequence of cancer treatment, poses significant challenges in healthcare. According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk. ImpediMed has the only FDA-cleared BIS technology for the clinical assessment of lymphedema. The Company's SOZO® Digital Health Platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with US payors now providing coverage for over 140 million covered lives. The PREVENT trial is a pivotal study and the largest randomized controlled trial to assess lymphedema prevention. The study enrolled 1,200 patients across 10 trial sites in the US and Australia, involving 13 hospitals, including Vanderbilt University, Mayo Clinic and MD Anderson. The trial was conducted over six and a half years and patients were followed for up to three years, with the primary aim to determine if early intervention in patients with subclinical detection of extracellular fluid accumulation via bioimpedance spectroscopy results in a lower rate of lymphedema progression versus the rate when tape measure is used for subclinical detection. The manuscript is published in Lymphatic Research and Biology. The results of the trial demonstrated that patients with early detection with L-Dex™ technology and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure. The difference is statistically significant (p=0.016) as well as being clinically significant for patients and clinicians. This represents an absolute reduction of 11.3% and relative reduction of 59% in lymphedema progression at three years.
공시 • Jan 23ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024ImpediMed Limited announced that they will report first half, 2024 results on Feb 27, 2024
공시 • Nov 20+ 2 more updatesImpediMed Limited Announces CFO ChangesImpediMed Limited announced leadership and Board changes to drive growth and manage costs. When elected, the Board announced a review of ImpediMed's strategy to ensure it was maximising the potential opportunities to transition to a high growth and profitable business. To date, the Board has considered the Company's operational readiness, approach to execution and cost structure. The review identified a very capable core management team, a distinctive product portfolio and an undeniable opportunity. However, more is needed to deliver robust execution and control costs. Given these challenges and the strong endorsement for change from ImpediMed shareholders at the recent General Meeting, the Board has determined that action now is appropriate. Tim Cruickshank has stepped down as CFO and the Board is discussing transition arrangements with him. Chair McGregor Grant assumes the responsibilities of CFO effective immediately, in an interim capacity and will be an Executive Chairman. The Chair, McGregor Grant will work closely with Dr. Bains as CFO, with a clear focus on managing costs. managing costs. For the last 12 years Mr. Grant was CFO and company Secretary of Nanosonics Limited. As well as leading financial strategy, Mr. Grant played a key role in developing and implementing corporate strategy. He was also responsible for operational functions including IT, legal and facilities management. During Mr. Grant's tenure at Nanosonics revenue grew from $2 million to $166 million. Together, Dr. Bains and Mr. Grant have extensive strategic, sales & marketing, financial and operational experience in high growth MedTech/healthcare businesses and will ensure stability and continuity of the business' operations. The Board recognises the significant talent within the senior management team, and Dr. Bains and Mr. Grant look forward to working closely with them to ensure the entire ImpediMed team remains focused on execution. Dr. Bains and Mr. Grant will also work closely with the management team to more deeply examine the Company's strategic and operational plans and its cost base to maximise the commercial opportunity and deliver value to its shareholders. Dr. Bains and Mr. Grant have been appointed to their roles in an interim capacity, which is expected to be in place for a period of up to six months while they assess the requirements of the business.
공시 • Oct 24ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023ImpediMed Limited announced that they will report Q1, 2024 results on Oct 31, 2023
공시 • Oct 12ImpediMed Limited, Annual General Meeting, Nov 30, 2023ImpediMed Limited, Annual General Meeting, Nov 30, 2023, at 10:01 E. Australia Standard Time.
공시 • Sep 27ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical OfficerImpediMed Limited announced the appointment of Steven Chen, MD, MBA as Chief Medical Officer effective 26 September 2023. Dr. Chen is a board-certified surgical oncologist who brings strong business acumen and extensive leadership experience in cancer care and the healthcare industry. Dr. Chen's previous leadership and experience: Chief Medical Officer of Avelas Biosciences, a clinical stage drug-device company dedicated to improving cancer care. Chief of Breast Surgery, University of California Davis Medical Center. Associate Program Director of the surgical oncology training program at City of Hope National Medical Center, Duarte, California. Past President, American Society of Breast Surgeons (ASBrS). Clinical training at the John Wayne Cancer Institute, the University of Michigan and the Center for Health Care Economics. Over 70 publications and 5,000 citations. The University of California Davis, the City of Hope, and the University of Michigan are members of the National Comprehensive Cancer Network (NCCN®). Most recently, Dr. Chen served as the Chief Medical Officer of Avelas, a clinical stage drug-device company dedicated to improving cancer care. There, he successfully oversaw their lead asset through Investigational New Drug (IND) application and first in human studies through pivotal trials and established the company's clinical strategy to support commercialisation and reimbursement. Previously, Dr. Chen served as the Chief of Breast Surgery at UC Davis Medical Center, followed by a position as an Associate Professor of Surgery and as the Associate Program Director of the surgical oncology training program at City of Hope National Medical Center in Duarte, California. He is a past President of the American Society of Breast Surgeons and serves or served on committees for a number of professional societies including the American Medical Association, the Society of Surgical Oncology, and the American College of Surgeons. Dr. Chen is a practicing surgeon in San Diego, California and the Director of Surgical Oncology at OasisMD. Dr. Chen received his medical degree and completed general surgery and critical care residencies at the University of Michigan, followed by a surgical oncology fellowship at the John Wayne Cancer Institute. Dr. Chen also obtained his master's in business administration at the University of Michigan's Ross School of Business.
공시 • Jul 17ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023ImpediMed Limited announced that they will report Q4, 2023 results on Jul 24, 2023
공시 • Jul 06ImpediMed Limited Appoints Daniel Sharp as DirectorImpediMed Limited appointed Mr. Daniel Sharp as director, date of appointment is July 1, 2023.
공시 • Jan 24ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023ImpediMed Limited announced that they will report Q2, 2023 results on Jan 30, 2023